© 2026 CellCarta - All rights reserved.
As a first adopter of digital whole slide imaging with two decades of digital pathology expertise, we have pioneered multiple imaging and image analysis methodologies that are ideal for clinical trial deployment. Our Global Digital Pathology and AI Consortium is one more way we continue to offer sponsors opportunities to apply innovative technologies.
We offer both flexible support for early-stage programs and rigorously validated image scanning and analysis for clinical trials, performed within our CLIA-certified, CAP-accredited laboratories.
CellCarta’s Innovative Digital Pathology and AI Solutions
✔ Pathologist-directed image analysis
Clinically validated AI solutions empowering earlier cancer detection and treatment decisions — including immune phenotyping, TME biomarker formation from H&E, and cell- and subcellular-level IHC quantification.
✔ Pathologist-directed image analysis
✔ Digital whole-slide scanning
✔ Multispectral imaging
✔ Customized and commercial algorithms
Seven partners. One AI-agnostic ecosystem
✔ Digital whole-slide scanning
✔ Multispectral imaging
✔ Customized and commercial algorithms
Lunit
The Lake Forest Expertise
Clinically validated AI solutions empowering earlier cancer detection and treatment decisions — including immune phenotyping, TME biomarker formation from H&E, and cell- and subcellular-level IHC quantification.
Seven partners. One AI-agnostic ecosystem.
Mindpeak
The Lake Forest Expertise
The frontier tissue-AI partner for precision oncology, turning IHC, H&E, and mIF images into reproducible, quantitative insights — from biomarker discovery to companion diagnostic rollout.
Imagene AI
The Lake Forest Expertise
Precision Oncology Intelligence through robust multimodal foundation models and proprietary real-world data, accelerating biomarker discovery, patient stratification, and response prediction.
DiPath AI
The Lake Forest Expertise
DiPath is a China-based AI-powered digital pathology company offering AI-enabled image analysis, whole-slide scanning, and workflow platforms for pathology research and biomarker development.
Nucleai
The Lake Forest Expertise
A tissue intelligence company applying AI-based image and clinical analysis to biopharma drug development, with a proven track record across ADC clinical programs.
Tivenix
The Lake Forest Expertise
AI-enabled bioinformatics and liquid biopsy, leveraging methylation biomarker data to assess organ-specific cell-death signals for early detection and stratification of neurodegenerative conditions.
Indica Labs
The Lake Forest Expertise
AI-powered digital pathology platforms and services supporting life science discovery, translational research, clinical workflows, and companion diagnostic development.
"AI in pathology is moving quickly. Sponsors need a scientifically credible, operationally controlled way to evaluate, validate and deploy the right AI approach for the right program"
Christopher Ung
Chief Scientific Business Officer, CellCarta
"Digital pathology and AI are becoming central to the next generation of biomarker development and patient selection. The opportunity is not to replace pathology — it is to make tissue, images and multi-omic data more quantitative, reproducible and actionable"
Ehab A. El-Gabry, MD
Chief Medical Officer & Head of CDx, CellCarta
Contact Our Digital Pathology Team
Our Global Digital Pathology and AI Consortium: Built for Clinical Research
Sponsors need a scientifically credible, operationally controlled way to evaluate, validate, and deploy the right AI approach for their program.
Our Global Digital Pathology and AI Consortium is a curated, AI-agnostic ecosystem that gives biopharma sponsors a single, trusted CRO laboratory partner to evaluate, validate, and deploy the right AI approach across digital pathology, image analysis, spatial biology, and precision diagnostics, at every stage of drug development.
The Consortium pairs CellCarta's pathologist-directed workflows, regulatory experience, and global laboratory operations with a hand-selected network of specialized AI innovators — including Lunit, Mindpeak, Imagene AI, Dipath AI, Nucleai, Tivenix and Indica Labs — creating a coherent, scientifically credible path from AI concept to trial-ready evidence across oncology, autoimmune, neurodegenerative, and beyond.
The consortium goes beyond access to AI tools, providing the infrastructure, expertise, and operational discipline to apply AI in real trials.
Ready to see where AI fits in your program?
CellCarta has two decades of digital pathology experience, as a first adopter of digital whole-slide, high-resolution image capture. Every algorithm in the Consortium runs on top of our rigorously validated, CLIA-certified, CAP-accredited laboratory infrastructure.
● Pathologist-directed image analysis
● Digital whole-slide brightfield and fluorescent scanning
● Multispectral imaging
● A dedicated team of imaging scientists, image analysts, and application experts, deploying both customized and commercial algorithms
Our image analysis portfolio already includes navify® by Roche, Indica Labs' HALO®, Visiopharm®, Akoya's inForm®, CyteHub®, SoloWeb, and Lunit SCOPE® — the Consortium extends this foundation with a broader, coordinated set of AI partners.
The infrastructure behind the ecosystem
CellCarta supports highly customized biomarker strategies and large-scale global studies across the full biomarker continuum — from translational research through clinical development and companion diagnostic (CDx) advancement. Connect with our team to explore how our owned laboratories across North America, Europe, Australia, and China can deliver globally consistent execution from a single, integrated partner.
About CellCarta
CellCarta supports highly customized biomarker strategies and large-scale global studies across the full biomarker continuum — from translational research through clinical development and companion diagnostic (CDx) advancement. Connect with our team to explore how our owned laboratories across North America, Europe, Australia, and China can deliver globally consistent execution from a single, integrated partner.
About CellCarta
Our Global Digital Pathology and AI Consortium: Built for Clinical Research
The frontier tissue-AI partner for precision oncology, turning IHC, H&E, and mIF images into reproducible, quantitative insights — from biomarker discovery to companion diagnostic rollout.
Precision Oncology Intelligence through robust multimodal foundation models and proprietary real-world data, accelerating biomarker discovery, patient stratification, and response prediction.
DiPath is a China-based AI-powered digital pathology company offering AI-enabled image analysis, whole-slide scanning, and workflow platforms for pathology research and biomarker development.
A tissue intelligence company applying AI-based image and clinical analysis to biopharma drug development, with a proven track record across ADC clinical programs.
AI-enabled bioinformatics and liquid biopsy, leveraging methylation biomarker data to assess organ-specific cell-death signals for early detection and stratification of neurodegenerative conditions.
AI-powered digital pathology platforms and services supporting life science discovery, translational research, clinical workflows, and companion diagnostic development.
Christopher Ung
"AI in pathology is moving quickly. Sponsors need a scientifically credible, operationally controlled way to evaluate, validate and deploy the right AI approach for the right program."
Chief Scientific Business Officer, CellCarta
Ehab A. El-Gabry, MD
"Digital pathology and AI are becoming central to the next generation of biomarker development and patient selection. The opportunity is not to replace pathology — it is to make tissue, images and multi-omic data more quantitative, reproducible and actionable"
Chief Medical Officer & Head of CDx, CellCarta
The infrastructure behind the ecosystem
Ready to see where AI fits in your program?
Tell us about your biomarker, CDx, or clinical trial challenge, and our team will help you identify the right path through the Consortium.